依达拉奉辅助治疗急性脑梗死60例临床观察

Clinical observation of 60 cases of acute cerebral infarction with edaravone adjuvant treatment

目的观察依达拉奉辅助治疗急性脑梗死的有效性和安全性。方法采用随机对照的方法,将符合急性脑梗死的120例患者,随机分为治疗组和对照组,每组各60例。2组均在常规药物治疗的基础上,治疗组将依达拉奉30mg加入到100mL0.9%生理盐水中静脉输注,2次/d,对照组静脉输注100mL0.9%生理盐水,2次/d,2组均治疗14d。对治疗前及治疗后48h、1周末、2周末进行神经功能缺损(NIHSS)评分比较,并对治疗前及治疗后临床疗效进行评价。结果治疗组神经功能缺损评分在治疗48h后与对照组相比无明显改善(P>0.05),在治疗1周末、2周末改善显著,差异具有统计学意义(P<0.05);治疗2周末治疗组临床疗效与对照组相比,差异具有统计学意义(P<0.05)。结论与单纯的常规药物治疗相比,依达拉奉辅助治疗急性脑梗死有较好的临床疗效,无明显不良反应。

Objective to investigate the clinical efficacy and safety profile of edaravone adjuvant treatment on the acute cer-ebral infarction.Methods 120 cases with acute cerebral infarction were divided into the treatment group and the control group randomly ,each with 60 patients. Both groups were treated with conventional approach.Further ,the treatment group was in-travenously given edaravone 30mg ,2 times a day ,for a total of 14 days ,while the control group was given？physiological sa-line correspondingly.The difference in neurological defects as well as clinical efficacies was evaluated between before treatment and 48 hours ,1 week ,2 weeks after treatment.Results as determined by NIHSS ,neurological deficit score of the treatment group in 1 week or 2 weeks was significantly lower than the control group （P〈0.05） ,though no significance observed in 48 hours. The clinical efficacy of the treatment group was not significantly better than the control group until 2 weeks （P〈0.05）.Conclusion Compared with conventional therapy alone ,edaravone adjuvant treatment of acute cerebral infarction has a good effect. Further ,no significant adverse reactions were observed.